Consequently, targeting OGFOD1 with identified inhibitors presents a promising therapeutic strategy to disrupt the translational adaptability of AML cells, potentially overcoming chemoresistance and improving patient outcomes. The gene discussed is OGFOD1; the disease is acute myeloid leukemia.